Brief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
08/10/2026 07:33
BRIEF-Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial Oct 8 (Reuters) - Cereno Scientific AB CRNOSb.ST:
CERENO SCIENTIFIC EXPECTS UP TO 15 SITES TO BE ACTIVATED BY YEAR-END 2026 IN THE GLOBAL PHASE IIB EPIMODE TRIAL; MAINTAINS Q4 2028 TIMELINE FOR TOPLINE RESULTS
MORE THAN 50% OF PLANNED SITES EXPECTED TO BE ACTIVATED BY END OF Q1 2027
TOPLINE RESULTS ANTICIPATED IN Q4 2028
PRIMARY ENDPOINT IS CHANGE IN PULMONARY VASCULAR RESISTANCE AFTER NINE MONTHS
Source text: ID:nMFN6NfGy2
Further company coverage: [CRNOSb.ST]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln